Isoindoline TNFα Inhibitors
Frontotemporal Dementia (FTD) and Alzheimer's disease (AD)
PreclinicalActive
Key Facts
Indication
Frontotemporal Dementia (FTD) and Alzheimer's disease (AD)
Phase
Preclinical
Status
Active
Company
About P2D Bioscience
Founded in 2016, P2D Bioscience is a private, preclinical-stage biotech developing novel therapeutics for CNS inflammatory disorders. Its pipeline features two distinct drug candidate classes: orally active isoindoline TNFα inhibitors for FTD and AD, and benztropine-analog dopamine transporter (DAT) inhibitors for ADHD. The company's strategy is to advance candidates through early clinical proof-of-concept before seeking partnerships for later-stage development and commercialization. P2D operates as a virtual or asset-centric company, leveraging experienced management and a focused platform to de-risk programs for potential partners.
View full company profile